ESR1 and breast carcinoma: This suggested that short-term treatment with anti-estrogens through the increase of Bcl-2 sensitizes ER+ breast cancer cells to BH3 mimetics, whereas resistance acquisition leads to a decrease in Bcl-2 levels and shifts the resistance mechanism to other anti-apoptotic factors [151].